@article{cd39c9588ab84092adb603c9f7a9c3c9,
title = "Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study",
keywords = "myelofibrosis, prognostic factors, quality of life, survival",
author = "Kosiorek, \{Heidi E.\} and Scherber, \{Robyn M.\} and Geyer, \{Holly L.\} and Srdan Verstovsek and Langlais, \{Blake T.\} and Mazza, \{Gina L.\} and Jason Gotlib and Vikas Gupta and Padrnos, \{Leslie J.\} and Palmer, \{Jeanne M.\} and Angela Fleischman and Mesa, \{Ruben A.\} and Dueck, \{Amylou C.\}",
note = "Funding Information: Heidi E. Kosiorek, Holly L. Geyer, Blake T. Langlais, Gina L. Mazza, Jeanne M. Palmer and Leslie J. Padrnos have nothing to disclose. Srdan Verstovsek has research support for conduct of clinical studies and honoraria for participation in advisory boards from Incyte. Srdan Verstovsek receives research support from Incyte, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma, Abbvie, Blueprint Medicines Corp., Novartis, Sierra Oncology, PharmaEssentia, Constellation, Italfarma, Protagonist, Kartos and does consulting work with Novartis, BMS and Incyte. Robyn M. Scherber was an employee of Incyte, the sponsor of the COMFORT‐I trial. Angela Fleischman does consulting work with Incyte, BMS, CTI, and PharmaEssentia. Jason Gotlib: Research Funding: Incyte, Novartis, Kartos, Blueprint Medicines, Deciphera, Cogent Biosciences, Abbvie, Celgene, BMS, Protagonist Therapeutics Advisory Boards/Consulting/Honoraria: Incyte, Novartis, Kartos, Blueprint Medicines, Deciphera, Cogent Biosciences, Abbvie, Protagonist Therapeutics, PharmaEssentia. Vikas Gupta received research support from Novartis, Abb Vie, and consulting fees from Novartis, BMS Celgene, Pfizer, Abb Vie, Roche, Incyte and Sierra Oncology. Ruben A. Mesa reports research support from Incyte, Genetech, CTI, Promedior and Abbvie; consultant for Novartis, Sierra Oncology and La Jolla Pharma. RH reports research support from Roche. Amylou C. Dueck receives royalties from commercial licensing of the Myeloproliferative Neoplasm Symptom Assessment Form. ",
year = "2022",
month = sep,
doi = "10.1111/bjh.18329",
language = "English (US)",
volume = "198",
pages = "1065--1068",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley and Sons Inc.",
number = "6",
}